Kamada (NASDAQ:KMDA) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.
Other equities analysts have also issued research reports about the stock. Jefferies Group reaffirmed a “buy” rating and set a $7.00 target price on shares of Kamada in a research report on Thursday, October 12th. Zacks Investment Research raised shares of Kamada from a “sell” rating to a “hold” rating in a research report on Wednesday, October 25th. One analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $8.50.
Shares of Kamada (NASDAQ:KMDA) traded down $0.05 during mid-day trading on Friday, reaching $5.20. 21,986 shares of the company were exchanged, compared to its average volume of 24,201. Kamada has a fifty-two week low of $3.75 and a fifty-two week high of $8.61. The company has a market capitalization of $211.73, a price-to-earnings ratio of -129.97 and a beta of 1.04. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.71 and a quick ratio of 2.73.
COPYRIGHT VIOLATION WARNING: “Kamada (KMDA) Raised to “Hold” at ValuEngine” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/05/kamada-kmda-raised-to-hold-at-valuengine.html.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.